Announcements Trials
Browse Landscape

Phase

Phase 4 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 6Lymphoid 2Gastrointestinal 2Other neoplasm 1Other hematologic neoplasm 1Myeloid 1CNS 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1

Interventions

Cyclophosphamide 342Rituximab 304Vincristine 157Doxorubicin 154venetoclax 153fludarabine 153Specimen Handling 152Prednisone 150Biopsy 122Magnetic Resonance Spectroscopy 117obinutuzumab 116Lenalidomide 109Dexamethasone 104Cytarabine 97ibrutinib 95Etoposide 92fludarabine phosphate 87Methotrexate 84acalabrutinib 78Bendamustine Hydrochloride 72zanubrutinib 71blinatumomab 63pembrolizumab 62CT-P10 60Gemcitabine 51Nivolumab 45glofitamab 44Calcium Dobesilate 44Mercaptopurine 43prednylidene 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thalidomide × Lymphoid × 1 year × Clear all
NCT02844309 2026-02-11

BDH-WM02

Institute of Hematology & Blood Diseases Hospital, China

Phase 4 Completed
44 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT02858804 2026-02-11

BDH-MCL01

Institute of Hematology & Blood Diseases Hospital, China

Phase 4 Completed
55 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡